| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner, See Remarks
2 companies
Venbio Global Strategic Fund III, L.P. last filed a Form 4 in July 2024, as 10% Owner, See Remarks at VTYX. The filings on record cover 2 companies.
At the last filing, the largest reported position was 1,936,637 shares of ARTV. Net of sales, the ARTV filings show accumulation of 416,666 shares.
Venbio Global Strategic Fund III, L.P. has 3 Form 4 filings on record from October 2021 to July 2024, across 2 companies: Artiva Biotherapeutics (ARTV), 2024; Ventyx Biosciences (VTYX), 2021–2022.
The 8 reported transactions were 3 conversions, 2 open-market purchases, 2 option or other derivative awards and 1 other transaction.
Counted by filing, the open-market trades come to 2 purchases worth about $10.0M and no sales.
The largest open-market purchase was 312,500 shares of VTYX at an average $16.00 on October 25, 2021, about $5.0M. Twelve months later VTYX was up 51%.
Shares as reported in the last Form 4 for each company; the most recent is from July 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.